JW SHINYAK CORPORATION
Financials
Valuation Metrics
JW SHINYAK CORPORATION's Market Cap is ₩1087B. At end of 2025 it was ₩1194B. Ranked #1188 of 2,436 in KR market (top 49%), #628 of 1,649 on KOSDAQ (top 38%), #137 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 59%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 108.66B KRW | KR#1,188/2,436 Sec#137/234 |
| Revenue | 82.77B KRW | KR#1,514/2,436 Sec#95/234 |
| Net Income | 9.75B KRW | KR#911/2,436 Sec#58/234 |
| Total Assets | 62.82B KRW | KR#2,056/2,436 Sec#178/234 |
| Net Assets | 42.88B KRW | KR#1,976/2,436 Sec#171/234 |
| Employees | 188 | KR#1,137/2,436 Sec#94/234 |
| Value | ||
| P/E | 11.15x | KR#777/2,436 Sec#43/234 |
| P/B | 2.53x | KR#2,038/2,436 Sec#157/234 |
| P/S | 1.31x | KR#1,583/2,436 Sec#92/234 |
| EV/EBITDA | 11.37x | KR#683/2,436 Sec#34/234 |
| FCF Yield | 4.08% | KR#931/2,436 Sec#53/234 |
| Profitability | ||
| ROE | 22.73% | KR#92/2,436 Sec#8/234 |
| ROA | 15.52% | KR#71/2,436 Sec#8/234 |
| Op. Margin | 11.69% | KR#407/2,436 Sec#35/234 |
| Revenue Growth | 8.77% | KR#973/2,436 Sec#88/234 |
| Earnings Growth | -68.89% | KR#1,276/2,436 Sec#84/234 |
| Financial Health | ||
| Debt Ratio | 146.49% | KR#1,143/2,436 Sec#131/234 |
| Total Debt | 1.50B KRW | KR#1,925/2,436 Sec#186/234 |
| FCF | 4.44B KRW | KR#935/2,436 Sec#65/234 |
| Cash | 191.4M KRW | KR#2,388/2,436 Sec#231/234 |
| Current Ratio | 1.72x | KR#1,133/2,436 Sec#121/234 |
| Net Debt/EBITDA | 0.14x | KR#706/2,436 Sec#47/234 |
| Dividend | ||
| Div. Growth | 0.00% | KR—/2,436 Sec—/234 |
| Performance | ||
| 1Y Return | 28.50% | KR#353/2,436 Sec#32/234 |
| 1M Return | 16.60% | KR#166/2,436 Sec#10/234 |
| From 52W High | -44.04% | KR#937/2,436 Sec#70/234 |
| 1Y MDD | -55.68% | KR#1,190/2,436 Sec#95/234 |
| Trading | ||
| Volume | 4,469,702 shares | KR#22/2,436 Sec#1/234 |
| Trading Value | 8.78B KRW | KR#271/2,436 Sec#32/234 |
| Foreign Own. | 2.03% | KR#1,093/2,436 Sec#107/234 |
| Per Share | ||
| EPS | 175 KRW | KR#1,246/2,436 Sec#87/234 |
| BPS | 767 KRW | KR#2,337/2,436 Sec#214/234 |
Company Info
Established in 1975, the company was listed on KOSDAQ in 2003 and rebranded as JW Shin Yak in 2016 after absorbing the former Joongwae Shin Yak in 2009. It manufactures and sells specialized pharmaceuticals, including antifungals and urological agents, serving the dermatology, urology, pediatrics, and internal medicine markets. JW Shin Yak is developing CAR-NK therapies using macrophage gene manipulation technology to enter the next-generation anti-cancer market and expand into the hair loss and cosmeceutical sectors. The company is headquartered in Gwacheon, Gyeonggi Province.